SC 13G: CytomX Therapeutics, Inc.

AI Summary

SC 13G filing by CytomX Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• sc13g.htm (SC 13G) — 98KB
• exhibit99-1.htm (EX-99.1) — 11KB
• 0000929638-24-001775.txt ( ) — 111KB

From the Filing

SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __) * CytomX Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23284F105 (CUSIP Number) May 2, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) ___________________________________ * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 Names of Reporting Persons. Cormorant Global Healthcare Master Fund, LP 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [x] 3 SEC Use Only 4 Citizenship or Place of Organization. Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 shares 6 Shared Voting Power 5,750,000 shares Refer to Item 4 below. 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 5,750,000 shares Refer to Item 4 below. 9 Aggregate Amount Beneficially Owned by Each Reporting Person 5,750,000 shares Refer to Item 4 below. 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A 11 Percent of Class Represented by Amount in Row (9)* 7.38% Refer to Item 4 below. 12 Type of Reporting Person (See Instructions) PN (Partnership) 1 Names of Reporting Persons. Cormorant Global Healthcare GP, LLC 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [x] 3 SEC Use Only 4 Citizenship or Place of Organization. Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 shares 6 Shared Voting Power 5,750,000 shares Refer to Item 4 below. 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 5,750,000 shares Refer to Item 4 below. 9 Aggregate Amount Beneficially Owned by Each Reporting Person 5,750,000 shares Refer to Item 4 below. 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A 11 Percent of Class Represented by Amount in Row (9)* 7.38% Refer to Item 4 below. 12 Type of Reporting Person (See Instructions) OO (Limited Liability Company) 1 Names of Reporting Persons. Cormorant Asset Management, LP 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [x] 3 SEC Use Only 4 Citizenship or Place of Organization. Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 shares 6 Shared Voting Power 5,750,000 shares Refer to Item 4 below. 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 5,750,000 shares Refer to Item 4 below. 9 Aggregate Amount Beneficially Owned by Each Reporting Person 5,750,000 shares Refer to Item 4 below. 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A 11 Percent of Class Represented by Amount in Row (9)* 7.38% Refer to Item 4 below. 12 Type of Reporting Person (See Instructions) PN (Partnership) 1 Names of Reporting Persons. Bihua Chen 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [x] 3 SEC Use Only 4 Citizenship or Place of Organization. United States Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 shares 6 Shared Voting Power 5,750,000 shares Refer to Item 4 below. 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 5,750,000 shares Refer to Item 4 below. 9 Aggregate Amount Beneficially Owned by Each Reporting Person 5,750,000 shares Refer to Item 4 below. 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A 11 Percent of Class Represented by Amount in Row (9)* 7.38% Refer to Item 4 below. 12 Type of Reporting Person (See Instructions) IN (Individual) Item 1. (a) Name of Issuer CytomX Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 Item 2. (a) Name of Person Filing Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Asset Management, LP Bihua Chen (b) Address

View Full Filing

View this SC 13G filing on SEC EDGAR